EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dose Optimization Design for Randomized Phase II Trials With Toxicity and Efficacy Endpoints

Ryuta Tabata, Tomohiro Ohigashi iD, Takashi Sozu iD

Pharmaceutical Statistics · 2026

DOI: 10.1002/pst.70112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2026. Verfasst von Ryuta Tabata und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Information and Computer Technology, Graduate School of Engineering, Tokyo University of Science, Tokyo, Japan. Hauptthemen laut MEDLINE: Clinical Trials, Phase II as Topic, Research Design, Endpoint Determination, Randomized Controlled Trials as Topic. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several study designs for identifying optimal biological dose (OBD) have been proposed for phase I, II, and I/II clinical trials, considering toxicity and efficacy of anticancer drugs, especially molecular‐targeted therapies and immune checkpoint inhibitors. Among these, the multiple‐dose randomized phase II trial (MERIT) design selects OBD candidates using hypothesis testing for toxicity and efficacy outcomes. However, it does not consistently control the type I error rate below the significance level, as the null hypothesis is defined only at specific points in a two‐dimensional null space. To address this limitation, we developed a design treating toxicity and efficacy as co‐primary endpoints, ensuring strict dose‐level type I error control across the entire null space. A Bonferroni correction addressed multiplicity in dose selection, providing overall type I error control. Unlike the existing method, the rejection region is determined analytically rather than by simulation, reducing computational costs. The type I error rate of the existing method exceeds the significance level in regions outside points considered in its sample size calculation. By contrast, the proposed method maintains the type I error rate below the significance level across the null space, though conservatively due to the co‐primary endpoint framework and Bonferroni adjustment. Required sample sizes of the proposed method tend to be larger than those of the existing one.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase II as TopicResearch DesignEndpoint DeterminationRandomized Controlled Trials as TopicAntineoplastic AgentsHumansDose-Response Relationship, DrugSample SizeComputer Simulation

Stichwörter der Autor:innen

Bonferroni correctionMERIT designbivariate Bernoulli distributionco‐primary endpointsoptimal biological doseproject optimus

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Information and Computer Technology, Graduate School of Engineering, Tokyo University of Science, Tokyo, Japan.
  • Department of Information and Computer Technology, Faculty of Engineering, Tokyo University of Science, Tokyo, Japan.

ORCID-Profile: Tomohiro Ohigashi, Takashi Sozu

Zitieren

APA

Tabata, R., Ohigashi, T., & Sozu, T. (2026). Dose Optimization Design for Randomized Phase II Trials With Toxicity and Efficacy Endpoints. Pharmaceutical Statistics. https://doi.org/10.1002/pst.70112

Vancouver

Tabata R, Ohigashi T, Sozu T. Dose Optimization Design for Randomized Phase II Trials With Toxicity and Efficacy Endpoints. Pharmaceutical Statistics. 2026. doi:10.1002/pst.70112

BibTeX
@article{Tabata2026,
  author = {Tabata, Ryuta and Ohigashi, Tomohiro and Sozu, Takashi},
  title = {Dose Optimization Design for Randomized Phase II Trials With Toxicity and Efficacy Endpoints},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  doi = {10.1002/pst.70112}
}
Kostenlos starten →